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1. Introduction 
Type 1 diabetes is a complex metabolic disease involving multiple organ systems which 
may cause severe visual impairment. Almost all parts of the eye may be affected including: 
the extra-ocular muscles, intra-ocular lens, the optic nerve, and retina. 
Diabetes is the leading cause of blindness between the ages of 20 and 74 in many developed 
countries (Cheung et al., 2010; Powers, 2008). Individuals with diabetes are 25 times more 
likely to become legally blind than individuals without diabetes. Blindness is primarily the 
result of diabetic retinopathy that accounts for ¼ of blind registrations in the western world 
(Cheung et al., 2010; Powers, 2008). 
Prevention of severe visual impairment in type 1 diabetes includes: optimal glycemic 
control, the treatment of ancillary risk factors such as hypertension, regular ophthalmic 
screening, and early diagnosis and treatment of ocular complications. 
In the following chapter we will describe the ocular complications of diabetes and the 
treatments for these conditions. 
2. Extra-ocular muscles 
Diabetics may present with a sudden onset of diplopia (double vision). This is usually 
caused by the partial or complete paralysis of one of the extra-ocular muscles due to 
microvascular damage to the third, fourth or sixth cranial nerve (Thomas & Graham, 2008; 
Kline et al. 2010). 
When a third cranial nerve palsy occurs, it is important to differentiate between a 
diabetic nerve palsy and paresis due to compression of the nerve from an aneurysm at 
the junction of the posterior communicating and internal carotid arteries. In diabetic 
nerve palsy the pupil is often spared meaning that it continues to react to light 
appropriately despite damage to the motor capabilities of the third cranial nerve. 
Typically in cranial nerve palsy due to a space occupying lesion such as an aneurysm, 
the pupil in the affected eye is dilated. In 20% of patients with diabetic nerve palsy there 
may be pupil involvement, however this is usually a mild efferent defect (Kline et al. 
2010). Aneurysms are rare in children but may be present in adolescents, so ruling it out, 
by neuroimaging, is crucial. Pain may also be present in diabetic third nerve palsy. When 
there is paresis of the fourth or sixth cranial nerve, referral to a neuro-ophthalmolgist is 
also recommended for follow-up and to exclude other causes, such as myasthenia gravis 
or brain lesions. 
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When the oculomotor defect is due to microvascular complications of diabetes the prognosis 
is good. 
Recovery of ocular motor function generally begins within three months of onset and 
recovery is usually complete. Although the diplopia can be debilitating, due to the generally 
limited course of these complaints, patients can usually be effectively managed 
conservatively with eye patching.  Surgery is rarely indicated. 
3. Lens: Cataract and refractive changes 
Hyperglycemia can reduce lens clarity. Hyperglycemia also induces changes in the 
refractive index and accommodative amplitude of the lens, both of which also act to reduce 
visual function (Flynn & Smiddy, 2000).  
3.1 Refractive and accommodative changes 
One of the most frequently encountered ocular manifestations of diabetes is abrupt changes 
in the refractive power of the lens. When the blood glucose level is high, the glucose 
concentration in the aqueous humor, the fluid surrounding the lens, increases as well.  This 
causes the glucose concentration in the lens to increase by diffusion (Flynn & Smiddy, 2000). 
Under normal conditions glucose is metabolized inside the lens by glycolysis. However, 
when the glucose level in the lens is very high, glycolysis enzymes are overridden and some 
glucose is reduced by the enzyme aldose reductase and converted to sorbitol (Stirban et al., 
2008). Sorbitol is metabolized slowly by the lens cells and accumulates, increasing the 
osmotic pressure inside the lens. This increased osmotic pressure leads to an influx of water 
from the aqueous humor and the lens swells. This larger lens is more convex and therefore 
more powerful at bending incoming light which alters the focal point of the eye, causing 
acute nearsightedness (myopia) and blurred distance vision.   
These refractive changes may be up to three to four diopters and may last for several weeks. 
Thus, patients with poorly controlled blood glucose levels experience transient refractive 
changes due to fluctuating levels of glucose in the blood. Acute blurring of vision may be 
the first symptom of undiagnosed or poorly controlled diabetes. 
Accommodation, the ability to adjust focus for near tasks such as reading, is also affected in 
patients with diabetes. Studies have shown that diabetics have decreased amplitude of 
accommodation compared to age matched controls, and require spectacle correction for near 
work at a younger age than non-diabetics (Flynn & Smiddy, 2000). 
3.2 Cataract 
Cataract is a common cause of visual impairment in patients with diabetes. Epidemiological 
studies have revealed an up to five-fold increased prevalence of cataracts in diabetic 
patients. Individuals with type 1 diabetes manifested a greater prevalence of cataracts 
between the ages of 18 to 44 than age-matched controls (Obrosova et al., 2010). Duration of 
diabetes and quality of glycemic control are the major risk factors for early cataract 
development. 
Potential mechanisms of diabetic cataract formation include accumulation of lenticular 
sorbitol, as described in the previous section (3.1). This reduces lens clarity leading to early 
cataract formation. It has also been postulated that recurrent high levels of glucose in the 
lens lead to the glycolation of lens proteins from increased non-enzymatic glycation and 
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oxidative stress to the lens (Obrosova et al., 2010). This causes diabetic patients to develop 
age related lens changes similar to non-diabetic age related cataracts, except at a younger 
age than non-diabetics (Bobrow et al. 2010). Several studies have analyzed the effect of 
vitamin and anti-oxidant supplements, such as vitamin C, E and beta carotene and zinc on 
preventing or slowing progression of age related cataracts in diabetes without showing any 
statistically significant benefit with their use (AREDS report no. 9, 2001 as cited in Obrosova 
et al., 2010). 
A rarer form of cataract in diabetics that is seldom encountered in clinical practice today is 
called the 'true diabetic cataract'.  This is typically seen in young patients with uncontrolled 
diabetes. Any rapidly maturing (i.e whitening) cataract in a child or a young adult should 
raise awareness to the possibility of diabetes. 
Cataract surgery is indicated when visual function is significantly impaired by the cataract. 
Surgery is also indicated if the cataract obscures the view of the retina and makes the 
diagnosis and treatment of diabetic retinopathy difficult. Cataract surgery is safe in diabetic 
patients and there is a 95% success rate in terms of improved visual acuity (Obrosova et al., 
2010).  Good glycemic control, fluid and electrolyte balance should be maintained 
perioperatively and the patient’s primary care physician and anesthesiologist should be 
involved. It is recommended that the surgery be scheduled in the morning to minimize 
changes in the patient’s usual schedule (Purdy et al., 2010). Some controversy exists 
regarding a potential association between cataract surgery and a subsequent worsening of 
diabetic retinopathy. Patients should be made aware of this risk pre-operatively. Cataract 
surgery and its effect on diabetic retinopathy will be discussed in more detail the diabetic 
retinopathy section (7.6.2). 
4. Cornea 
Structural changes to the corneal basement membrane in diabetes decrease the adhesion of 
corneal epithelial cells to the deeper stromal tissue. This increases the risk of recurrent 
corneal erosions (Reidy et al., 2010). In addition, accumulation of sorbitol in the cornea 
during periods of hyperglycemia leads to hypoesthesia (a loss of corneal sensation). Both 
hypoesthesia and epithelial adhesion dysfunction occur more frequently with increased 
severity and duration of diabetes. In these patients, any epithelial injury, either from trauma, 
during ocular surgery or from routine contact lens use, may result in prolonged healing 
times. This increases the risk of severe complications such as bacterial infiltration and 
ulceration.  
5. Iris and pupil 
Bilateral tonic pupils may be seen in diabetic patients (Kline et al., 2010). This manifests with 
sluggish, segmented pupillary reactions to light and better response to near effort, followed 
by slow redilation of the pupil. Tonic pupils are caused by microvascular damage to 
postganglionic parasympathetic pupillomotor nerve fibers. Diminished pupillary response 
is also seen due to glycogen infiltration of the pigment epithelium and sphincter and dilator 
muscles (Thomas & Graham, 2008). 
Rubeosis iridis, neovascularization in the iris, is a serious complication of diabetes which 
occurs in patients with severe diabetic retinopathy (Thomas & Graham, 2008). Growth 
factors released from the ischemic retina induce the development of intertwining blood 
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vessels on the anterior surface of the iris (figure 1). These vessels can block the normal 
drainage of fluid from the anterior chamber, leading to a sharp and persistent rise in 
intraocular pressure. This complication is known as neovascular glaucoma. This type of 
glaucoma is often refractory to treatment and can be associated with pain from very high 
ocular pressure. Topical medical therapy used commonly in other forms of glaucoma is 
often less effective. Treatment should include aggressive control of the underlying retinal 
disease with peripheral laser ablation to reduce ischemia. The treatment of proliferative 
diabetic retinopathy will be discussed in more detail in section 7.6.2.3. 
 
 
Fig. 1. Neovascularization of the Iris: These pathologic blood vessels on the iris (white 
arrows) are associated with retinal ischemia in proliferative diabetic retinopathy. The 
normal iris has no visible surface blood vessels. 
6. Optic nerve 
6.1 Diabetic papillopathy 
In diabetic papillopathy, chronic swelling of the optic disc often associated with mild visual 
impairment. The suspected cause is mild reversible ischemia of the optic nerve head (Ostri 
et al., 2010; Kline et al., 2010). Risk factors include pronounced recent decrease in 
hemoglobin A1C and a small cup to disc ratio of the optic nerve head. Patients often present 
with no visual complaints or with a mild nonspecific visual disturbance such as mild 
distortion or blurring. There is no pain and visual acuity is usually normal but may be 
slightly diminished. There is no afferent pupillary defect. An enlarged blind spot is seen on 
visual fields. Clinical examination reveals unilateral or bilateral hyperemic edema of the 
optic disc, accompanied by dilation of inner disc surface vessels, vascular leakage and 
axonal swelling (cotton wool spots). These enlarged vessels may be confused with 
neovascularization of the disc but these radially dilated vessels do not extend into the 
vitreous (Figure 2). 
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Fig. 2. Diabetic Papillopathy. A chronic swelling of the optic disc often associated with mild 
visual impairment. This color fundus photograph shows blurred disc margins (white 
arrows), flame shaped hemorrhages (black arrowhead). The dilated blood vessels on the 
optic disc (black arrow) may be confused with neovscularization but are radially dilated, do 
not enter the vitreous cavity and do not leak on fluorescein angigraphy.[ marked by the 
white arrowhead the pointer aiding the patient’s fixation during photography]. 
When diabetic papillopathy is suspected, it is important to perform fluorescein 
angiography. In diabetic papillopathy, dye leakage is limited to the disc and peripapillary 
retina as opposed to the intravitreal leakage seen in the case of neovascular lesions. 
Diabetic retinopathy is usually present at diagnosis, but in 20% of reported cases there 
was no clinical evidence of any diabetic retinopathy (Kline et al., 2010). If the optic disc 
edema is bilateral, the initial evaluation should include brain imaging and lumbar 
puncture to rule out intracranial space occupying lesions and elevated intracranial 
pressure.  
The optic disc edema resolves in many cases without treatment, usually within two to ten 
months. Minimal optic atrophy is seen in 20% of cases. In rare cases, especially in poorly 
controlled patients, diabetic papillopathy may progress to non-arteritic anterior ischemic 
optic neuropathy (NAION) with significant optic atrophy and arcuate visual field defects. In 
most cases, long term visual acuity depends on the associated diabetic retinopathy. There is 
no proven treatment for diabetic papillopathy. 
6.2 Non-arteritic anterior ischemic optic neuropathy (NAION) 
Non-arteritic anterior ischemic optic neuropathy (NAION) occurs as a consequence of the 
interruption of blood flow to the optic nerve at the level of the optic disc. NAION is 
characterized by diffuse or segmental, hyperemic or pale optic disc edema. It is usually 
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unilateral, and in contrast to diabetic papillopathy, damage to the optic nerve ganglions 
causes decreased visual acuity and/or visual field loss. Vision is usually not worse than 
20/200 and the typical visual field defect is altitudinal. Diabetes is a risk factor for 
NAION and the condition may present at a younger age in diabetic patients (Kline et al., 
2010).  
After an episode of NAION visual acuity may be stable but can also decline slowly over 
weeks to months until eventual stabilization. The initial finding upon examination is optic 
disc swelling, but this resolves over time and is replaced by optic disc atrophy within 4-8 
weeks. There is no proven treatment for this condition. 
7. Diabetic retinopathy 
Damage to the retinal capillaries and other small vessels is the hallmark of diabetic eye 
disease and is known as diabetic retinopathy. This condition is the major cause of blindness 
and visual disability in patients with type 1 diabetes. 
7.1 Epidemiology 
Diabetic retinopathy is one of the most frequent causes of blindness in working aged adults 
(20-74 years) (Regillo et al., 2010; Cheung et al., 2010). In the USA an estimated 86% of 
patients with type 1 diabetes have some degree of diabetic retinopathy. Data from the 
Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR) showed that within 5 
years of diagnosis of type 1 diabetes, 14% of patients developed retinopathy, with the 
incidence rising to 74% by 10 years (Klein et al., 2008; Varma, 2008). In people with 
retinopathy at the WESDR baseline examination, 64% had their retinopathy worsen, 17% 
progressed to proliferative diabetic retinopathy (PDR) and about 20% developed diabetic 
macular edema during 10 years of follow-up. 
The WESDR data in type 1 diabetics showed that 25 years after diagnosis, 97% of 
patients developed retinopathy, 43% progressed to PDR, 29% developed diabetic 
macular edema and 3.6% of patients younger than 30 at diagnosis were legally blind 
(Klein et al., 2008). Fortunately, recent advances in glycemic control, ophthalmic 
treatment and patient education seem to be working. The WESDR results also showed a 
reduction in the yearly incidence and progression of diabetic retinopathy during the past 
15 years (Varma 2008). 
The course of diabetic retinal disease in children is fairly benign. Severe complications such 
as proliferative diabetic retinopathy are uncommon in children before puberty (Raab et al., 
2010). 
7.2 Risk factors 
Several risk factors influence the development and progression of diabetic retinopathy. The 
following list contains most of the important risk factors known today. 
1. Diabetes duration: The longer the duration of diabetes, the higher the risk of developing 
diabetic retinopathy and of having a severe manifestation of the disease. (Simon et al., 
2010; Cheung et al., 2010). 
2. Hyperglycemia:  Good glycemic control has been shown to significantly prevent the 
development and progression of diabetic retinopathy. Every 1% decrease in 
hemoglobin A1C leads to a 40% reduction in the risk of developing retinopathy, a 25% 
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reduction in the risk of progression to vision threatening retinopathy and a 15% 
reduction in the risk of blindness (Cheung et al. 2010, DCCT group, 1995). 
3. Hypertension: Good blood pressure control is important in reducing the risk of 
retinopathy. Every 10 mmHg reduction in systolic blood pressure leads to a reduction 
of 35% in the risk of retinopathy progression and a reduction of 50% in the risk of visual 
loss (Cheung et al. 2010). 
4. Hyperlipidemia: High cholesterol may also be a risk factor for diabetic retinopathy 
progression (Cheung et al., 2010). 
5. Genetic factors:  The Diabetes Control and Complications Trial (DCCT group, 1997) 
showed a heritable tendency for developing diabetic retinopathy, regardless of other 
risk factors. 
6. Ethnicity: Diabetic retinopathy in America is more prevalent among African Americans, 
Hispanic and south Asian groups than in Caucasians with otherwise similar risk 
profiles (Cheung et al., 2010). 
7. Pregnancy: Pregnancy is associated with worsening of diabetic retinopathy (DCCT 
group, 2000). All pregnant women need to be closely monitored throughout pregnancy. 
Pregnancy in type 1 diabetes is discussed in further detail in section 7.6.1. 
7.3 Pathophysiology 
The normal retina has a blood–retinal barrier (BRB) which consists of cells that are tightly 
joined together to prevent certain substances from entering the retinal tissue. An important 
part of the BRB is the non-fenestrated capillaries of the retinal circulation. In diabetic 
retinopathy, damage to retinal blood vessels leads to a breakdown of the BRB and the 
leakage of fluid, blood and protein into the retinal tissue. 
Diabetic retinopathy is induced when hyperglycemia and other causal risk factors trigger a 
cascade of biochemical changes leading to microvascular damage in the retina. 
Hyperglycemia leads to rise of sorbitol concentrations via the action of aldose reductase. 
This process increases oxidative stress by reducing intracellular levels of reduced 
glutathione, an important antioxidant (Stirban et al., 2008). Intracellular hyperglycemia also 
increases synthesis of diacylglycerol an activating cofactor for protein kinase C (PKC). 
Activated PKC decreases the production of anti-artherosclerotic factors and increases 
production of pro-artherogenic factors, pro-adhesive and pro-inflammatory factors (Stirban 
et al., 2008). Hyperglycemia also leads to accumulation of advanced glycated end products 
which are pro-inflammatory and activate PKC (Stirban et al., 2008). Intracellular 
hyperglycaemia increases intracellular N-acetylglucosamine levels. This byproduct reacts 
with serine and threonine residues in transcription factors, resulting in pathologic changes 
in gene expression (Stirban et al., 2008). The final consequence of these pathological 
processes is increased inflammation and increased oxidative stress which cause endothelial 
cell dysfunction in retinal blood vessels. 
Endothelial cell dysfunction induces retinal arteriolar dilatation which increases capillary 
bed pressure. This results in microaneurysm formation, vessel leakage and rupture 
(Cheung et al., 2010). Vascular permeability is also increased from loss of pericytes and 
increased endothelial proliferation in retinal capillaries. The breakdown of the blood-
retinal barrier allows fluid to accumulate in the deep retinal layers where it damages 
photoreceptors and other neural tissues. This is the mechanism by which macular edema 
reduces visual acuity.  
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In some capillaries there is endothelial cell apoptosis.  Vessels become acellular leading to 
vascular occlusion and non-perfusion of local retinal tissue (Stirban et al., 2008). The 
resultant retinal ischemia promotes the release of inflammatory growth factors, such as 
vascular endothelial growth factor (VEGF), growth hormone- insulin growth factor and 
erythropoietin (Cheung et al., 2010). These factors influence neovascularization, the 
proliferation of new capillaries, which is the hallmark of proliferative diabetic retinopathy.  
7.4 Classification and clinical features  
Diabetic retinopathy is classified into two stages: non-proliferative diabetic retinopathy 
(NPDR) and proliferative diabetic retinopathy (PDR). In NPDR the vascular changes occur 
within the retina and do not cross the retinal surface. The more advanced stage of PDR is 
marked by neovascularization wherein new blood vessels grow out from the retinal surface 
towards the vitreous cavity.  
A major cause of vision loss in diabetic retinopathy is diabetic macular edema (DME). DME 
occurs when leaky capillary beds allow fluid to accumulate in the part of the retina 
responsible for central vision. This edema can occur in patients with any stage of underlying 
retinopathy from mild NPDR to severe PDR.  
Visual impairment is usually related to the state of macular disease and the consequences of 
neovascularisation such as vitreous hemorrhage and retinal detachment. As such, the level 
of retinal disease does not always correlate with visual function and severe diabetic 
retinopathy can be present initially without significant visual loss.  
7.4.1 Non-proliferative diabetic retinopathy (NPDR) 
In NPDR the retinal microvascular changes occur within the retina and do not extend 
beyond the surface of the retina. The patient with NPDR is usually asymptomatic and visual 
acuity is preserved unless the macula is affected. 
Clinical findings include microaneurysms (saccular enlargements of weakened capillaries), 
intra-retinal hemorrhages, hard exudates (lipid filled macrophages), cotton wool spots 
(nerve fiber layer infarcts)(figures 3-4), venous beading (focal venous dilatations and 
constrictions) and intra-retinal microvascular abnormalities (IRMA’s, dilated pre-existing 
capillaries) (Regillo et al., 2010, Cheung et al., 2008). 
Fluorescein angiography (FA) is an essential tool for evaluating the retinal circulation and 
retinopathy stage. Sodium fluorescein is injected into the systemic circulation, and an 
angiogram is obtained by photographing the fluorescence emitted after illumination of the 
retina. In NPDR, the FA shows microaneurysms as dye filled outpouchings. Hemorrhages 
appear as black dots as the blood obscures the fluorescence from the retina and choroid 
below (figure 5). 
NPDR is classified as mild, moderate or severe, reflecting the risk of progression to PDR 
(Table 1) as determined by the Early Treatment in Diabetic Retinopathy Study (ETDRS) 
(ETDRS group, 1995). The diagnosis of severe NPDR is made when one of three findings 
is present: diffuse intra-retinal hemorrhages and microaneurysms in all 4 retinal 
quadrants, venous beading in 2 quadrants or one intra-retinal microvascular 
abnormalities anywhere. Fifteen persent of patients with severe NPDR will progress to 
high-risk PDR within 1 year. When any two features of severe NPDR are present, the 
patient is said to suffer from very severe NPDR and the one year risk of progression to 
high risk PDR increases to 45%. 
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Fig. 3. A: Color photograph of normal fundus (left eye) normal optic disc (white arrow) and 
macula (black arrow). B: Color photograph (right eye) showing non-proliferative diabetic 
retinopathy and macular edema. Findings include; dot and blot hemorrhages (black 
arrows), flame shaped hemorrhages (white arrow),  and cotton wool spot (white arrowhead) 
which represent nerve fiber layer infarcts. Hard exudates (black arrowheads) are lipid filled 
macrophages and in this photograph are radially distributed around the central macula. 
 
 
 
 
 
Fig. 4. Color photograph of fundus with moderate non-proliferative diabetic retinopathy 
with macular edema. Multiple dot and blot retinal hemorrhages are seen (white 
arrowheads) and hard exudates (black arrows). 
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Fig. 5. Fluorescein angiography of non proliferative diabetic retinopathyof the right eye. 
Sodium fluorescein is injected into the systemic circulation, and an angiogram is obtained 
by photographing the fluorescence emitted after illumination of the retina. In NPDR the FA 
shows microaneurysms filled with dye (small white arrows). Hemorrhages appear as black 
dots because the transmission of fluorescence from below the hemorrhage is blocked (white 
arrowheads) . The optic disc marked with long white arrow. 
 
Stage of NPDR Clinical Features Progression Risk 
Mild NPDR Few microaneurysms 5% progress to PDR within 
1 year 
Moderate NPDR Microaneurysms and other 
microvascular lesions  
12-16% progress to PDR 
within 1 year 
Severe NPDR   
(Meets 1 of 3 criteria) 
 Extensive intraretinal 
hemorrhages and 
microaneurysms in all four 
quadrants 
 Venous beading in two or 
more quadrants  
 One IRMA  
52% progress to PDR 
within 1 year 
 
15% progress to high risk 
PDR within 1 year 
Very severe NPDR Any two of the features of 
severe NPDR 
45% progress to high risk 
PDR within 1 year 
Table 1. Clinical classification of non-proliferative diabetic retinopathy 
7.4.2 Proliferative diabetic retinopathy (PDR) 
Diabetic retinopathy advances to the proliferative stage when new vessels 
(neovascularizations) are formed which grow up from the retina towards the vitreous 
cavity. The development of these pathological blood vessels is induced by pro-angiogenic 
factors released as a result of the severe retinal ischemia caused by the progression of 
diabetic retinal microvascular disease.  Neovascularizations can be identified clinically as a 
jumble of disorganized, fine vessels emanating from the organized retinal vessel 
architecture (figure 6). Fluorescein angiography is also very effective at identifying 
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neovascular lesions as the new vessels are porous and leak fluorescent dye into the vitreous 
cavity.  
The new vessels in PDR evolve in three stages. Initially, the fine new vessels grow with 
minimal fibrous tissue. Then the new vessels increase in gauge and length with an increased 
fibrous component. Finally, the vessels regress and the residual fibrovascular tissue along 
the posterior surface of the vitreous body contracts.  
Retinal neovascularizations (NV) are divided into two subtypes based on their relative risk 
of causing severe visual loss as demonstrated by the Diabetic Retinopathy Study (DRS). 
Vascular proliferations on or near the optic disc are termed NV-disc (NVD) and 
proliferations elsewhere are termed NV-elsewhere (NVE) (figures 6 - 8). The presence of 
NVD carries the higher risk of severe visual loss and requires more urgent treatment (DRS 
research group, 1979, 1981). 
 PDR is graded from early to high risk based on the risk of severe visual loss as determined 
by the extent of the neovascular proliferations. The DRS (DRS research group, 1979, 1981) 
defined high risk PDR as the presence of either: NVD with a vitreous hemorrhage, NVD 
larger than a quarter disc area without vitreous hemorrhage or NVE larger than half disc 
area with vitreous hemorrhage. Without treatment, patients with early PDR have 50% risk 
of developing high risk PDR in 1 year and those with high risk PDR have a 25% risk of 
severe visual loss within 2 years. Treatment of PDR involves extensive peripheral laser 
ablation of the retina and is discussed in section 7.5.2.3. 
 
 
 
 
 
 
 
Fig. 6. Proliferative Diabetic Retinopathy with Neovascularization of the Optic Disc (NVD). 
Vascular proliferations on or near the optic disc are termed NV-disc (NVD).This Color 
photograph shows fine jumbled vessels (black arrows) typical of NVD. Multiple dot and 
blot retinal hemorrhages are seen (white arrows). 
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Fig. 7. High Risk Proliferative Diabetic Retinopathy with Large NVD. PDR is graded from 
early to high risk based on the risk of severe visual loss as determined by the extent of the 
neovascular proliferation. A: Color photograph showing a large neovascularization of the 
optic disc (black arrows) this NVD is larger than a quarter disc area therefore consistent 
with high risk PDR. Retinal hemorrhages (white arrows) and hard exudates (white 
arrowheads) are also seen. B: Fluorescein angiography in the same patient demonstrating 
hyper-fluorescence due to dye leakage from the disc neovascularization (white arrows). 
 
 
Fig. 8. High Risk Proliferative Diabetic Retinopathy with large NVE. This neovascular lesion 
located away from the optic disc is known as a Neovascularization-Elsewhere (NVE). This 
large NVE (black arrow) is associated with a small hemorrhage (white arrow). 
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The most frequent complication of PDR is vitreous hemorrhage (figure 9) caused by rupture 
in the fragile neovascular vessels. The initial complaint is often of black dots partially 
obscuring vision and can evolve to severe visual loss over a period of hours to days as the 
eye fills with blood.  
 
 
Fig. 9. Vitreous Hemorrhage. Vitreous hemorrhage is the most frequent complication of 
PDR. It is caused by rupture of neovascular vessels. This color figure shows partial vitreous 
hemorrhage causing general haze. Dense blood in the vitreous cavity is seen (white 
arrowheads). This hemorrhage occurred in eye after the initiation of pan-retinal 
photocoagulation as a treatment for PDR. Multiple white-yellow laser burns are seen (black 
arrows). This treatment is discussed in section 7.5.2.3. The optic disc is also seen (white 
arrow). 
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Another cause of severe vision loss in PDR is traction retinal detachment. This detachment 
occurs when the neovascular tissue connecting the retinal surface to the vitreous contracts 
causing a separation between the surface and deep retinal layers (figure 10). If this occurs in 
the center of the macula severe vision loss can result. 
 
 
Fig. 10. Traction Retinal Detachment. This detachment is one of the serious complications in 
PDR and may cause severe visual loss. It occurs when the neovascular tissue connecting the 
retinal surface to the vitreous contracts causing a separation between the surface and deep 
retinal layers. This color fundus photograph shows elevated and detached retina (black 
arrowheads) involving the optic disc area (white arrow). The retina at the center of the 
macula (black arrow) is not detached. 
A third serious complication of PDR occurs when proliferative and pro-angiogenic factors 
released from the ischemic retina induce the propagation of new vessels on the iris (figure 
1). These vessels can block the normal outflow of fluid from the eye causing often severely 
increased ocular pressure. This complication is known as neovascular glaucoma and is 
discussed further previously in section 5. 
Visual acuity in the absence of macular disease is often good in PDR until a complication 
occurs, most commonly vitreous hemorrhage. This sudden transition from good vision to 
near blindness can be traumatic for patients who were unaware of the severity of their 
diabetic eye disease. 
7.4.3 Diabetic macular edema  
Diabetic macular edema (DME) is responsible for most of the moderate visual loss in 
retinopathy patients. The vision loss is often mild at first, but without effective 
treatment it can progress and patients can lose the ability to perform activities of daily 
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living such as reading and driving. Diabetic macular edema is assessed separately from 
the stage of retinopathy (NPDR/PDR) and it can manifest along a different and 
independent course. 
The edema evolves when damage to the macular capillary bed causes a breakdown of the 
blood-retina barrier. This results in increased retinal vascular permeability and to the 
accumulation of fluid in the macula. Macular edema may be ‘focal’ and emanate from a 
small cluster of leaky vessels, or ‘diffuse’ and involve the entire macula without a clear point 
of origin. Clinical examination can reveal rings of hard exudates (lipid filled macrophages) 
which delineate the area of focal leakage (figures 3 & 4). These subtypes are often 
differentiated by angiography which demonstrates areas of focal leakage from specific 
capillary lesions and microaneurysms in focal edema. In diffuse macular edema, 
angiography reveals widespread leakage with no definitive point of origin from extensive 
breakdown of the blood-retinal barrier (Regillo et al., 2010).   
Treatment decisions are based on the clinical examination in DME. Intervention is 
recommended only when the retinal edema involves or threatens the center of the macula. 
In all other cases, close follow-up alone is indicated (ETDRS group, 1995).  
Optical Coherence Tomography (OCT) is a useful ancillary imaging technique in DME. 
Recent technological advances in OCT technology have provided ophthalmologists with 
high-resolution images of the retina in cross-sectional slices. Aside from demonstrating 
areas of retinal thickening and intra-retinal fluid (figure 11), OCT obtains quantitative 
measurements of central retinal thickness that are important for close monitoring and 
follow-up of macular edema. Serial OCT examinations are often used as a non-invasive 
and accurate method analyzing treatment response in DME patients (Cheung et al., 
2008).  
 
  
Fig. 11. Optical Coherence Tomography (OCT) of the Macula. A: OCT scan demonstrating 
the normal anatomic indentation in the central macula in a healthy eye (white arrow). B: 
Diabetic macular edema: There is loss of central macular indentation due to retinal cysts 
(white arrow). Hard exudates are also seen (white arrowhead). 
7.4.4 Diabetic macular ischemia 
Macular ischemia is a devastating complication of diabetic retinopathy. It is caused by 
extensive loss of retinal capillary perfusion in the macula. Clinical exam often reveals 
microaneurysms clustering at the margins of the non-perfused retina. Angiography can 
demonstrate the presence and extent of the area with capillary non-perfusion. This entity is 
generally associated with significantly decreased vision (Regillo et al., 2010). 
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7.5 Treatment and prevention of diabetic retinopathy  
The main goal of treatment of diabetic retinopathy is preventing complications which can 
lead to vision loss. Treatment should include both ocular therapy and systemic medical 
intervention. 
7.5.1 Medical treatment 
Hyperglycemia, hypertension and hyperlipidemia are known risk factors for the 
development and progression of diabetic retinopathy. Treating and controlling these factors 
is crucial to preventing and limiting disease progression. 
The Diabetes Control and Complications Trial (DCCT group, 1995) showed that intensive 
glycemic control reduced both the risk of developing retinopathy and the rate of 
progression of existing retinopathy. Intensive glycemic control reduced the risk for 
progression to severe NPDR and PDR, the incidence of diabetic macular edema and the 
need for laser treatments. Every percent reduction in hemoglobin A1C lowers the risk of 
retinopathy development by 30-40%.  
Several other systemic therapies have been investigated and found to reduce the risk of 
retinopathy progression including Angiotensin Converting Enzyme Inhibitors, Protein 
Kinase C Inhibitors and inhibitors of Advanced Glycosylation End-products formation 
(Cheung et al., 2008). 
7.5.2 Ocular treatment 
Ocular therapy in diabetic retinopathy includes panretinal or focal laser photocoagulation, 
intravitreal injections of either steroids or inhibitors of Vascular Endothelial Growth Factor 
(VEGF), surgery or a combination of the aforementioned treatments. The suitable treatment 
regimen must be tailored individually for each patient and is based on clinical status of the 
patient (ocular and systemic), previous treatments and data from several reports and 
ongoing studies. 
7.5.2.1 NPDR 
Visual acuity is not usually affected in NPDR unless there is damage to the macula in the 
form of macular edema or ischemia. Ocular treatment at this stage is definitively indicated 
only if there is evidence of macular disease. In patients with very severe NPDR who are at 
high risk for progression to PDR, laser treatment can be considered if the patient is not 
considered a suitable candidate for close follow-up. In such cases the recommended 
treatment is Pan- Retinal laser Photocoagulation (PRP) which will be discussed in section 
7.5.2.3 (ETDRS group, 1995).  
7.5.2.2 Diabetic macular edema (DME)  
Treatment options for DME include focal laser photocoagulation, intravitreal injections of 
either steroids or anti-VEGF compounds and surgery. 
7.5.2.2.1 Focal laser  
The mainstay of DME treatment is focal laser photocoagulation. Focal laser treatment for 
DME involves the application of discrete laser burns to areas of leakage in the macula. The 
treatment is not painful and can be repeated up to every 4 months if edema persists. 
Treatment criteria are based on the ETDRS recommendations (ETDRS group, 1995) which 
showed that eyes with macular edema involving or threatening the central macula, defined 
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as clinically significant macular edema (CSME), benefited from focal laser treatment. Focal 
laser treatment reduced the risk of moderate visual loss (loss of three lines of vision) by 50% 
over two years, increased the chance of improved vision and reduced central macular 
thickness compared to no treatment.  
In eyes with macular edema that does not meet the criteria for CSME, laser treatment is not 
indicated. Close follow-up is recommended to determine the progression of the macular 
edema. Unfortunately, when the macular edema is associated with macular ischemia from a 
loss of macular capillary perfusion, the ETDRS showed a lesser beneficial effect for focal 
laser (ETDRS Group, 1995). 
Side effects of focal laser photocoagulation include: paracentral visual field loss, transiently 
increased macular edema with decreased visual acuity and choroidal neovascularization 
(Regillo et al, 2010).  
7.5.2.2.2 Steroid injections 
Inflammatory factors play an important role in the development of diabetic retinopathy and 
macular edema (see section 7.3). For this reason it has long been thought that ocular steroid 
injections may be beneficial in DME treatment. Several trials have shown modestly 
improved visual acuity and central macular thickness after injection of intravitreal 
Triamcinolone (Grover at al., 2008; Yilmaz et al., 2009). A few recent trials on long acting 
steroid implants, such as Fluocinolone Acetate or Dexamethasone, have also reported short 
term visual acuity improvements (Grover et al., 2009).   
The Diabetic Retinopathy Clinical Research Network (DRCR network, 2008) compared 
intravitreal injection of Triamcinolone to focal laser treatment in eyes with DME. There was 
no difference in visual acuity between the two groups after 1 year, and at 2 years eyes 
treated with laser had better vision. However, complications of intravitreal steroids, 
including elevated ocular pressure and increased cataract progression limit the usefulness of 
these drugs in DME. Intravitreal sterioid injections may be considered in patients who have 
previously undergone cataract surgery and in cases where the macular edema is refractory 
to focal laser. In these cases the injections may be given either alone or as an adjunct to laser 
treatment (Gillies et al., 2006; Maia et al., 2009). 
7.5.2.2.3 Anti-vascular endothelial growth factor (VEGF) compounds 
Vascular Endothelial Growth Factor (VEGF) is a major cause of the increased retinal 
vascular permeability which causes macular edema (Stirban et al., 2008). Several VEGF 
inhibitors have been investigated as treatments for DME with a beneficial effect on visual 
acuity and central macular thickness. 
Injection of intravitreal Pegaptanib, a pegylated aptamer that inhibits one isoform of VEGF, 
was found to be better than sham injections in improving in visual acuity and decreasing the 
need for focal laser treatment, in the Macugen Diabetic Retinopathy Study group 
(Cunningham et al., 2005). 
The injection of monoclonal antibodies that block all isoforms of VEGF has also been 
investigated as a treatment for DME. Several studies have shown a beneficial effect on visual 
acuity in eyes treated with Bevacizumab (trade name Avastin), a recombinant full length 
humanized antibody to VEGF (Nicholson & Shachat, 2010). Based on data from multiple 
studies (Nicholson & Shachat, 2010) repeated doses of Bevacizumab increase its average 
positive effect. The optimal timing for repeat dosing is unclear, but is probably between 3 to 
12 weeks, with maximal effect with a 3 to 6 weeks interval between treatments.  
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The Bevacizumab Or Laser Treatment study (Michaelidis et al., BOLT study, 2010) 
compared 6-weekly bevacizumab injections to focal laser treatment in DME. One year post-
randomization, eyes treated with bevacizumab had significantly better vision by over one 
line of acuity and less macular edema compared to eyes treated with focal laser. 
Bevacizumab treated eyes also had fivefold greater odds gaining at least 2 lines of vision.  
Another promising drug that targets VEGF is Ranibizumab (trade name Lucentis). This a 
recombinant, humanized antibody fragment binds and inhibits all isoforms of VEGF. A recent 
study compared four treatment options; monthly injections of Ranibizumab combined with 
focal laser, monthly Ranibizumab alone with the option for rescue focal laser treatment, focal 
laser treatment alone and focal laser combined with intravitreal injections of Triamcinolone 
(DRCR network 2010a). After 1 year, eyes that received intravitreal injections of Ranibizumab, 
either combined with laser or with the option for rescue laser had better visual acuity 
compared with the other treatment groups. On average, eyes receiving Ranibizumab gained 1 
line in visual acuity after 1 year. Half of Ranibizumab treated patients gained more than 2 lines 
in visual acuity, and 30% gained 3 lines or more. Two years results showed a similar positive 
treatment effect in DME with Ranibizumab injections.  
The injection of anti-VEGF agents to the vitreous is both effective and safe. Adverse ocular 
effects include: cataract formation, retinal detachment, vitreous hemorrhage and infection. 
Potential systemic adverse effects include: hypertension, stroke, and myocardial infarction 
but these are very uncommon (Cheung et al., 2010; Nicholson & Shachat, 2010). 
7.5.2.2.4 Surgical intervention 
DME can also be treated surgically by performing a vitrectomy. This option is used 
sparingly because of the utility of both laser treatments and intravitreal injections in 
controlling the disease. Surgery is indicated in cases refractory to other treatments or when 
there is mechanical traction on the macula from vitreo-retinal adhesions. In such cases 
edema resolution can often not be obtained without resorting to intraocular surgery where 
the traction can be definitively released (Kaiser et al., 2001; DRCR network, 2010b).  
7.5.2.3 Proliferative diabetic retinopathy (PDR) treatment 
7.5.2.3.1 Panretinal photocoagulation (PRP) 
The goal of treatment in PDR is to prevent complications and lower the risk of severe 
vision loss. The mainstay of treatment for PDR is laser ablation of the peripheral retina. In 
this treatment, known as panretinal photocoagulation (PRP), laser burns are placed over 
the entire retina, sparing only the central macula (figure 12). PRP promotes the regression 
and arrest of progression of retinal neovascularizations by destroying ischemic retinal 
tissue and reducing ischemia driven VEGF production (Cheung et al., 2010; Regillo et al., 
2010).  
The Diabetic Retinopathy Study (DRS) evaluated efficacy of PRP treatment in eyes with 
advanced NPDR or PDR (DRS Group, 1981). The DRS study recommended prompt 
treatment in eyes with high risk PDR (defined in section 7.4.2), because these eyes had the 
highest risk for severe visual loss. PRP treatment in these patients reduced the risk of severe 
visual loss by 50% over 5 years. The ETDRS study found that PRP treatment in eyes with 
early PDR reduced the risk of progression to high risk PDR by 50%, and significantly 
reduced the risk of severe visual loss (ETDRS Group, 1995). Based on these results, PRP 
treatment should be considered in eyes with any stage PDR especially if there is poor 
metabolic control, a non compliant patient or difficulty in maintaining close follow-up. 
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Fig. 12. Pan-Retinal Photocoagulation. The mainstay of treatment for PDR is laser ablation of 
the peripheral retina. In this treatment, known as panretinal photocoagulation (PRP), laser 
burns are placed over the entire retina (small black arrows), sparing only the central macula 
(large black arrow) and the optic disc (white arrow). 
Full PRP treatment as recommended by the DRS and the ETDRS includes as many as 4000 
laser burns. PRP can be painful and is often performed over several sessions. After the initial 
treatment course, additional therapy can be applied if there is persistent neovascularisation. 
After treatment, proliferative retinal tissue may regress and contract causing a vitreous 
hemorrhage or a traction retinal detachment from contracture of fibrovascular tissue. Side 
effects of PRP treatment also include; decreased in night vision, decreased color vision and 
loss of peripheral vision. These side effects can be reduced by spreading out the treatment 
sessions and by using less energy at each session (Regillo et al. 2010). 
When PDR presents with macular edema, PRP treatment may initially increase the amount 
of the edema (ETDRS Group, 1991). In such case it is recommended to treat the macular 
edema with either focal laser or an intravitreal injection before initiating PRP (Silva et al., 
2009, Mirshani et al., 2008). 
7.5.2.3.2 Vitreous hemorrhage 
In patients with new onset vitreous hemorrhages, laser PRP treatment is recommended if 
visualization of the retina is adequate. A severe, dense, non-clearing vitreous hemorrhage is 
an indication for vitrectomy surgery. The Diabetic Retinopathy Vitrectomy Study (DRVS 
Group, 1985) recommended surgery within 1 to 6 months of vitreous hemorrhage onset in 
type 1 diabetes patients with a non-clearing vitreous hemorrhage. Early vitrectomy 
improved visual acuity outcomes compared with waiting up to a year for spontaneous 
resolution before resorting to surgery.  
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Recent advances in vitreoretinal surgery, including smaller gauge instruments and the 
ability to perform laser ablation during surgery, have changed treatment recommendations. 
If a patient with a vitreous hemorrhage has not previously undergone PRP, vitrectomy is 
recommended when a dense vitreous hemorrhage persists beyond one to three months. 
Patients with vitreous hemorrhage that have preexisting complete PRP may undergo a 
longer observation period (Regillo et al., 2010).  
Several studies have evaluated the efficacy of intravitreal anti-VEGF injections in 
patients with PDR (Nicholson & Shachat, 2010). Intravitreal Bevacizumab as adjunctive 
therapy with PRP was found to decrease leakage area from neovascularizations, improve 
visual acuity outcomes and reduce macular edema compared with PRP alone. In eyes 
with PDR and a dense vitreous hemorrhage preventing full PRP treatment, a 
Bevacizumab injection has been shown to aid significantly in clearing the hemorrhage 
(Moradian et al., 2008).  
Bevacizumab has also been shown to enhance retinal surgery in patients with PDR.  A single 
Bevacizumab injection given 1-2 weeks before vitrectomy for vitreous hemorrhage, results 
in decreased bleeding during surgery, decreased operating time and less post operative 
vitreous hemorrhage as compared to vitrectomy alone (Nicholson & Shachat, 2010; 
Ahmadieh et al.,2009). 
7.5.2.3.3 Traction retinal detachment 
Traction retinal detachment from the contraction of the neovascular tissue connecting the 
retinal surface to the vitreous is another serious complication of PDR. However, traction 
detachments which do not involve the macula can remain stable for years. Vitrectomy 
surgery is indicated only when the traction retinal detachment involves or threatens the 
central macula or if a retinal tear develops (Regillo et al. 2010). 
7.5.2.3.4 Neovascular glaucoma 
A third serious complication of PDR occurs when high levels of VEGF in the retina 
induce the development of new vessels on the iris. These vessels threaten to block the 
outflow of aqueous fluid from the eye and raise ocular pressure. The treatment of 
patients with neovascularisation of the iris involves both the minimization of retinal 
ischemia and the aggressive reduction of intraocular pressure if elevated. Retinal 
ischemia is treated with aggressive and extensive ablation of peripheral retinal tissue 
with PRP regardless of the stage of PDR. Injection of intravitreal anti-VEGF agents as 
adjunctive therapy to PRP can induce a rapid reduction or resolution of 
neovascularisation of the iris (Ahmadieh et al., 2009; Wasik et al., 2009). However, these 
injections should be seen as an adjunct to full PRP which remains the definitive 
treatment and not as a viable replacement.  
Elevated ocular pressure in neovascular glaucoma is treated initially with topical 
medications. Often multiple drops are required to reduce pressure to below the target 
level of approximately 20 millimeters of mercury. In advanced cases, topical treatment 
alone may not be sufficient and systemic treatment with carbonic anhydrase inhibitors 
such as Acetazolamide may be considered. Common side effects of Acetazolamide 
include numbness and tingling in the fingers and toes, and taste alterations. 
Acetazolamide also increases the risk of dehydration and metabolic acidosis. Serial 
electrolyte and kidney function tests are recommended in all patients receiving this 
medication. 
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In refractory cases Cyclodestructive procedures are required if medical therapy fails to 
provide symptomatic relief. With cyclocryotherapy, the IOP-lowering effect is achieved by 
destroying secretory ciliary epithelium and/or reducing blood flow to the ciliary body. It is 
indicated as a last resort only if relief of pain is the main goal. 
7.6 Special considerations 
7.6.1 Diabetic retinopathy in pregnancy 
In women with preexisting diabetes, pregnancy is considered an independent risk factor for 
the development and progression of diabetic retinopathy (Shultz et al., 2005). Gestational 
diabetes, in absence of preexisting diabetes does not show a similar association with diabetic 
retinopathy. Most of the progression of diabetic retinopathy in pregnancy occurs by the end 
of the second trimester. Although regression of retinopathy usually occurs postpartum, 
there is still an increased risk for progression during the first year postpartum (Shultz et al., 
2005). Risk factors for the development and progression of diabetic retinopathy in 
pregnancy include longer duration of diabetes before conception, rapid normalization of 
hemoglobin A1C at the beginning of pregnancy, poor glycemic control during pregnancy, 
diabetic nephropathy, high blood pressure and preeclampsia (Shultz et al., 2005; Vestgaard 
et al., 2010).  
Severity of diabetic retinopathy before or at beginning of pregnancy is also a strong 
predictor of progression of retinopathy during and after pregnancy. The Diabetes in Early 
Pregnancy Study (Chew et al., 1995) showed that 10.3% of women without diabetic 
retinopathy and 18.8% with mild NPDR experienced retinopathy progression during 
pregnancy, and 6.3% of women with mild NPDR progressed to PDR. In women with 
moderate NPDR, 54.8% suffered retinopathy progression and 29% developed PDR. Overall, 
progression to sight threatening diabetic retinopathy, including macular edema and PDR, 
occurs in 6% of pregnant diabetic women (Vestgaard et al., 2010).  
Progression of retinopathy during pregnancy is probably related to the hypervolemic and 
hyper-coagulable states in pregnancy, as well as elevated pro-inflammatory and angiogenic 
factor levels. This results in capillary occlusion and leakage aggravating diabetic retinopathy 
mechanisms (Shultz et al., 2005; Kastelan et al., 2010). Ideally, good glycemic control and full 
treatment of pre-existing diabetic retinopathy complications should be attained before 
conception. 
All diabetic women who plan pregnancy should be referred by their treating physician to an 
ophthalmologist. The recommended follow-up of pregnant women with type 1 diabetes 
includes an ophthalmologic exam at the beginning of pregnancy and during the first 
trimester. Subsequent follow-up depends on the stage of diabetic retinopathy found on the 
initial examinations. In women with no retinopathy or very mild NPDR, an ophthalmologic 
exam is indicated when there are visual complaints. In moderate NPDR an exam should be 
done at least once during the second trimester and every 4-6 weeks during the third 
trimester. In severe NPDR and PDR, close follow-up is needed, and an exam should be done 
every 4-6 weeks, from the beginning of the second trimester.  
Treatment of diabetic retinopathy during pregnancy includes maximal control of both 
glucose levels and blood pressure (Vestgaard et al., 2010).  Ocular therapy such as PRP 
should definitely be performed for PDR and be strongly considered in cases of severe 
NPDR. Disease progression can be very fast in pregnancy and waiting for PDR to clearly 
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develop may result in severe complications that necessitate invasive surgery. Ocular therapy 
for PDR and macular edema during pregnancy can include PRP, focal laser and intravitreal 
injections of Triamcinolone. Although there is not much data on the safety of intravitreal 
injections of anti-VEGF agents during pregnancy, the literature includes some reports on the 
safe and effective use of Bevacizumab (Tarantola et al., 2010). 
7.6.2 Cataract surgery in patients with diabetic retinopathy  
Cataract is a major factor which compromises vision in diabetic patients. While diabetics 
may benefit from cataract extraction, a controversy exists in the ophthalmic community as 
to whether cataract surgery potentiates diabetic retinopathy progression. Several studies 
have reported worsening of diabetic retinopathy and macular edema after surgery 
(Pollack et al., 1991; Hauser et al., 2004; Jaffe et al., 1992, Hayashi et al., 2009). Progression 
was seen during the first year after surgery and was highest in the first 3 months post-
operatively. A review of several other studies, especially in the cataract surgery era using 
the smaller incision phacoemulsification technique, showed no significant progression of 
diabetic retinopathy and macular edema after surgery (Rashid & Young, 2010; Shah & 
Chen, 2010). Overall, diabetics with cataracts benefit from surgery, and improved visual 
acuity is reported in 92-94% of patients (Rashid & Young, 2010). The combined evidence 
suggests that in patients with low risk or absent diabetic retinopathy and no clinically 
significant macular edema at the time of surgery, there is little increased risk of 
retinopathy progression. However, in patients with severe NPDR, PDR or significant 
macular edema, cataract surgery carries an increased risk for retinopathy progression and 
a worse visual acuity outcome. 
Recent studies have shown a potential benefit using intravitreal injection of Bevacizumab 
at the end of cataract surgery (Cheema et al., 2009; Chen et al., 2009; Nicholson & 
Shachat, 2010) especially in cases with poorly controlled or refractory macular edema 
and diabetic retinopathy before surgery. Patients who received intravitreal Bevacizumab 
enjoyed better outcomes in terms of visual acuity, macular thickness and retinopathy 
progression. 
A thorough evaluation of patients with diabetes is warranted before cataract surgery. 
Patients who have severe NPDR or PDR should be considered for PRP treatment prior to 
cataract removal (Chew et al., 1999). Patients with clinically significant macular edema 
should undergo treatment, such as focal laser or intravitreal injection of anti- VEGF agents 
pre-operatively. Ideally, surgery should be delayed until stabilization of retinopathy and 
macular edema is achieved. In refractory cases, adjunctive therapy with an anti-VEGF agent 
at the end of cataract surgery should be considered. Close post-operative follow-up with an 
ophthalmologist is highly recommended in all patients with preexisting diabetic 
retinopathy. 
8. Schedule for ophthalmologic examinations 
Regular ocular examination can detect early ocular disease such as cataracts and glaucoma 
as well as retinopathy. Diabetic retinopathy in type 1 diabetes is rare during the first 5 years 
after diagnosis, so the baseline ophthalmologic examination could be extended to 5 years 
after diagnosis if blood glucose has been well controlled. In children with pre-pubertal 
diabetes, the baseline examination should be done at puberty (Raab et al. 2010). 
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The timing and frequency of follow-up ocular examinations depends on individual patient’s 
status. In high risk patients with long term diabetes and poor systemic risk factor control 
annual examinations should be performed even in the absence of retinopathy. In patients 
with known retinopathy, the examination schedule is based on the degree of retinopathy, 
and on the patient’s compliance and adherence to regular follow-up. In more advances 
stages such as PDR and when macular edema is present, more frequent and careful follow-
up is suggested. (Regillo et al., 2010). Table 2 shows the recommended schedule for follow–
up.  
 
Retinopathy Stage Follow-up Schedule 
Normal or rare microaneurysms Annually 
Mild NPDR Every 9 months 
Moderate NPDR Every 6 months 
Severe NPDR Every 2-4 months 
Clinically significant macular edema  Every 2-4 months  
PDR Every 2-3 months (careful follow-up) 
Table 2. Suggested time table for follow-up in diabetic retinopathy (modified from the 
Preferred Practice Patterns committee, retina panel, diabetic retinopathy, American 
Academy of Ophthalmology, 2003, as cited in Regillo et al., 2010).  
9. Summary 
Management of type 1 diabetes involves close cooperation between the treating primary 
physician and the many specialists who help manage the complications of this disease. 
Recent advances, including intraocular anti-VEGF injections, have added important new 
tools which minimize vision loss in diabetic eye disease. Proactive, interdisciplinary 
coordination of treatment and timely referrals can aid in the minimization of visually 
threatening complications, significantly enhancing patient quality of life.  
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